Basic Study

CR6-interacting factor-1 contributes to osteoclastogenesis by inducing receptor activator of nuclear factor κB ligand after radiation

Li-Xin Xiang, Qian Ran, Li Chen, Yang Xiang, Feng-Jie Li, Xiao-Mei Zhang, Yan-Ni Xiao, Ling-Yun Zou, Jiang F Zhong, Shengwen Calvin Li, Zhong-Jun Li

Abstract

BACKGROUND

Radiation induces rapid bone loss and enhances bone resorption and adipogenesis, leading to an increased risk of bone fracture. There is still a lack of effective preventive or therapeutic method for irradiation-induced bone injury. Receptor activator of nuclear factor κB ligand (RANKL) provides the crucial signal to induce osteoclast differentiation and plays an important role in bone resorption. However, the mechanisms of radiation-induced osteoporosis are not fully understood.

AIM

To investigate the role of CR6-interacting factor-1 (Crif1) in osteoclastogenesis after radiation and its possible mechanism.

METHODS

C57BL/6 mice were exposed to Co-60 gamma rays and received 5 Gy of whole-body subletal irradiation at a rate of 0.69 Gy/min. For in vitro study, mouse bone marrow mesenchymal stem/stromal cells (BM-MSCs) were irradiated with Co-60 at a single dose of 9 Gy. For osteoclast induction, monocyte-macrophage RAW264.7 cells were cocultured with mouse BM-MSCs for 7 d. ClusPro and InterProSurf were used to investigate the interaction interface in Crif1 and protein kinase cyclic adenosine monophosphate (cAMP)-activated catalytic
INTRODUCTION

Exposure to radiation, such as accident or terrorism, radiotherapy for cancer, and astronauts on exploratory missions beyond low-Earth orbit, can cause rapid bone loss and increase the risk of bone fracture [1,2]. Astronauts on exploratory missions beyond low-Earth orbit, can cause rapid bone loss and increase the risk of bone fracture [1,2].

RESULTS

Crip1 expression increased in bone marrow cells after radiation in mice. Overexpression of Crip1 in mouse BM-MSCs and radiation exposure could increase RANKL secretion and promote osteoclastogenesis in vitro. Deletion of Crip1 in BM-MSCs could reduce both adipogenesis and RANKL expression, resulting in the inhibition of osteoclastogenesis. Deletion of Crip1 in RAW264.7 cells did not affect the receptor activator of nuclear factor kB expression or osteoclast differentiation. Following treatment with protein kinase A (PKA) agonist (forskolin) and inhibitor (H-89) in mouse BM-MSCs, Crip1 induced RANKL secretion via the cAMP/PKA pathway. Moreover, we identified the Crip1-protein kinase cyclic adenosine monophosphate-activated catalytic subunit alpha interaction interface by in silico studies and shortlisted interface inhibitors through virtual screening on Crip1. Five compounds dramatically suppressed RANKL secretion and adipogenesis by inhibiting the cAMP/PKA pathway.

CONCLUSION

Crip1 promotes RANKL expression via the cAMP/PKA pathway, which induces osteoclastogenesis by binding to receptor activator of nuclear factor kB on monocytes-macrophages in the mouse model. These results suggest a role for Crip1 in modulating osteoclastogenesis and provide insights into potential therapeutic strategies targeting the balance between osteogenesis and adipogenesis for radiation-induced bone injury.

Key words: Irradiation; Osteoporosis; Bone marrow; Mesenchymal stem cells; Monocyte macrophage; Bone

Citation: Xiang LX, Ran Q, Chen L, Xiang Y, Li FJ, Zhang XM, Xiao YN, Zou LY, Zhong JF, Li SC, Li ZJ. CR6-interacting factor-1 contributes to osteoclastogenesis by inducing receptor activator of nuclear factor kB ligand secretion and adipogenesis. World J Stem Cells 2020; 12(3): 222-240

URL: https://www.wjgnet.com/1948-0210/full/v12/i3/222.htm
DOI: https://dx.doi.org/10.4252/wjsc.v12.i3.222

Core tip: Current treatment of osteoporosis is based mainly on inhibiting bone resorption or stimulating bone generation to increase bone mass; however, the side-effects of some drugs affect long-term administration and adherence. There is still a lack of effective preventive or therapeutic method for radiation-induced bone injury. Because of the contribution of adipocytes to osteoporosis, future drug screening should target not only the regulation of the balance between bone formation and bone resorption but also the balance between osteogenic and adipogenic differentiation. Here, through screening, we identified five CR6-interacting factor-1 inhibitors targeting CR6-interacting factor-1-protein kinase cyclic adenosine monophosphate-activated catalytic subunit alpha interaction interface that could dramatically reduce receptor activator of nuclear factor kB ligand secretion and adipogenesis. Our study provides insights into potential therapeutic strategies for radiation-induced bone injury.
three times as much as that of the population of women who do not receive radiotherapy\(^3\). Osteoporosis is often a long-term complication of radiotherapy, which is characterized by an imbalance in skeletal turnover with reduced bone formation and enhanced bone resorption\(^4\). Current treatment of osteoporosis is based mainly on inhibiting bone resorption or stimulating bone generation to increase bone mass; however, the side-effects of some drugs affect long-term administration and adherence. There is still a lack of effective preventive or therapeutic method for irradiation-induced bone injury\(^5\).

Bone homeostasis is maintained by various types of cells, such as osteoblasts and osteoclasts, which are differentiated from different stem cells in the bone marrow. Osteoblasts are the bone-forming cells derived from bone marrow mesenchymal stem/stromal cells (BM-MSCs) and play an important role in the regulation of bone mass\(^6\). Meanwhile, osteoclasts are large, multinucleated cells derived from hematopoietic progenitors of the monocyte-macrophage lineage. Osteoclasts are the principal cells capable of resorbing bone and play an essential role in bone remodeling\(^7\). The differentiation of osteoclast is mainly regulated by macrophage colony-stimulating factor, receptor activator of nuclear factor κB ligand (RANKL), and osteoprotegerin (OPG). Macrophage colony-stimulating factor is required for the survival and proliferation of osteoclast precursors, but RANKL and OPG play central roles in the activation of osteoclastogenesis\(^8\). By binding to receptor activator of nuclear factor κB (RANK) (on hematopoietic progenitors), RANKL provides the crucial signal to induce osteoclast differentiation from hematopoietic progenitor cells as well as to activate mature osteoclasts. OPG is a soluble decoy receptor that can bind to RANKL and negatively regulate RANKL binding to RANK\(^9\). BM-MSCs, osteocytes, osteoblasts, adipocytes, and activated T and B lymphocytes are the main sources of RANKL secretion. RANKL expression is promoted by radiation, inflammation, cytokines, hormones, and a number of other agents, including those that signal through protein kinase A (PKA), glycoprotein 130, and vitamin D receptor\(^10,11\). Following radiation exposure, BM-MSCs appear to preferentially differentiate into adipocytes instead of osteoblasts, which results in a reduction of bone formation and an increase in bone marrow fat accumulation\(^12,13\). And the irradiation-induced bone loss is also associated with increased osteoclast numbers and resorbing surfaces of osteoclasts lining trabeculae\(^14\). However, the molecular mechanisms of cell fate decisions in the differentiations of BM-MSCs and osteoclasts involved in irradiation-induced bone loss are still not fully understood.

CR6-interacting factor-1 (Crif1) is a multifunctional protein that can interact with many proteins to induce cell cycle arrest, modulate oxidative stress and cell radiosensitivity, and regulate transcriptional activity through interactions with the DNA-binding domains of transcription factors\(^15-21\). It is also the constitutive protein of the large mitoribosomal subunit required for the synthesis and insertion of mitochondrial-encoded OxPhos poly peptides into the mitochondrial membrane\(^22\). Crif1 deficiency in macrophages impairs mitochondrial oxidative function and causes systemic insulin resistance and adipose tissue inflammation\(^23\). Our previous study showed that Crif1 promotes adipogenic differentiation of BM-MSCs after radiation by modulating the cyclic adenosine monophosphate (cAMP)/PKA signaling pathway\(^24\).

In this study, we investigated the role of Crif1 in osteoclastogenesis after radiation. Here, we showed that Crif1 deletion caused decreases in RANKL expression and the RANKL/OPG ratio and reduced osteoclastogenesis and adipo genesis after radiation. Through screening, we also identified five compounds that could effectively inhibit RANKL expression and adipogenesis. We demonstrated that Crif1 promoted osteoclastogenesis by inducing RANKL expression via the cAMP/PKA pathway. Our study suggests a role for Crif1 in modulating osteoclastogenesis and provides insights into potential therapeutic strategies targeting the balance between osteogenesis and adipogenesis for radiation-induced bone injury.

**MATERIALS AND METHODS**

**Animals**

The animal protocol was designed to minimize pain or discomfort to the animals. All animal studies performed were approved by the Laboratory Animal Welfare and Ethics Committee Of the Third Military Medical University. C57BL/6 mice (aged 12-14 wk) were purchased from Beijing HFK Bio-Technology Co. Ltd. Mice were maintained under specific pathogen-free conditions and fed standard mouse chow and water. For radiation treatment, mice (n = 6/group) were exposed to Co-60 gamma rays and received 5 Gy of whole-body sublethal irradiation at a rate of 0.69 Gy/min.
Cell culture and treatment

For in vitro study, mouse BM-MSCs purchased from Cyagen Biosciences were cultured in mouse mesenchymal stem cell medium (MUCMX-90011, Cyagen Biosciences) at 37 °C in an atmosphere containing 5% CO₂.

For radiation treatment, mouse BM-MSCs were irradiated with a single dose of 9 Gy Co-60 at a rate of 0.69 Gy/min. RAW264.7 cells were cultured in Dulbecco’s modified Eagle medium (HyClone) supplemented with 10% fetal bovine serum.

For osteoclast induction, RAW264.7 cells (2 × 10⁴/well) seeded in the upper well and mouse BM-MSCs (5 × 10⁴/well) seeded in the lower well of a 12-well transwell unit (0.4 µm) were cocultured for 7 d with or without forskolin (25 µmol/L) or H-89 (20 µmol/L) treatment. After 7 d of coculture, cells were collected for real-time quantitative polymerase chain reaction (RT-qPCR) and Western blot analysis; meanwhile, the supernatant medium was collected for enzyme linked immunosorbent assay (ELISA).

Human bone marrow mesenchymal stem/stromal cells (H-BM-MSCs) (catalogue No. 7500, ScienCell) were cultured in mesenchymal stem cell medium (catalogue No. 7501, ScienCell) at 37 °C in an atmosphere containing 5% CO₂.

Micro-computed tomography analysis

Femurs were dissected, fixed overnight in 4% paraformaldehyde, and stored in 1% paraformaldehyde at 4 °C. Trabecular bone parameters were measured in the distal metaphysis of the femur. We started analysing slices at the bottom of the distal growth plate, where the epiphyseal cap structure completely disappeared, and continued for 95 slices (10.5 µm/slice, using SCANCO VivaCT40) towards the proximal end of the femur.

Isolation of bone marrow cells

Femurs were collected and cleaned in sterile phosphate buffered saline (PBS), and both ends of each femur were trimmed off. Bones were placed in a 0.6-mL microcentrifuge tube that was cut open at the bottom and nested inside a 1.5-mL microcentrifuge tube. Fresh bone marrow was spun out by brief centrifugation (from 0 rpm to 10000 rpm, 9 s). Red blood cells were lysed using RBC lysis buffer (catalog No. RT122-02, TIANGEN). After centrifugation (3000 rpm, 5 min), cells in the bottom layer were collected for Western blot and RT-qPCR assays.

Crif1 knockout and overexpression in vitro

For Crif1 overexpression, mouse BM-MSCs were transfected with a Crif1 lentiviral overexpression vector (pLV[Exp]-EGFP:T2A:Puro-EF1A>mGadd45gip1[NM_183358.4]) constructed by Cyagen Biosciences (vector ID: VB180112-1182ypt) and selected with 5 µg/mL puromycin dihydrochloride (A1113803, Invitrogen). An empty vector (pLV[Exp]-EGFP:T2A:Puro-Null, vector ID: VB160420-1011mqh, Cyagen Biosciences) was included as a control.

For Crif1 knockout, mouse BM-MSCs were first transfected with lentiCas9-Blast vector (Genomeditech) and selected with 5 µg/mL blasticidin S HCl (A1113903, Invitrogen). Then, cells were transfected with CRISPR/Cas9 M_Gadd45gip1 gRNA vector (target sequence: GCGGGGGCGCACGGTAGCTG, Genomeditech) and selected with 5 µg/mL puromycin dihydrochloride. An empty vector (LentiGuide-Puro-Scramble-gRNA, Genomeditech) was included as a control.

In vitro adipogenic differentiation

To induce adipogenesis, mouse BM-MSCs were seeded at a density of 2 × 10⁴ cells per well in 6-well plates and cultured in mouse mesenchymal stem cell adipogenic differentiation medium (MUCMX-90031, Cyagen Biosciences). Human BM-MSCs were seeded at a density of 2 × 10⁴ cells per well in 6-well plates and cultured in human mesenchymal stem cell adipogenic differentiation medium (HUXMA-90031, Cyagen Biosciences). After 21 d of differentiation, we preserved the supernatant medium for ELISA and fixed the cells with 2 mL of 4% formaldehyde solution for 30 min. Then, the cells were stained with 1 mL of oil red O working solution (catalog No. S0131, Cyagen Biosciences) for 30 min and visualized under a light microscope (Leica DMIRB, Heidelberg, Germany). The dye from oil red O staining was extracted using isopropanol, and the optical density at 510 nm was measured using a Varioskan FLASH microplate reader.

Western blot analysis and antibodies

Protein expression in the samples was analysed by Western blot. Briefly, total protein lysates were extracted with cell lysis buffer for Western blot and immunoprecipitation (catalog No. P0013, Beyotime) and denatured by boiling. Protein samples were resolved on 12% SDS-polyacrylamide gels and transferred to polyvinylidene fluoride
membranes (Western Blotting Membranes; Roche). Membranes were blocked in PBS containing 5% (w/v) nonfat dry milk and 0.1% Tween 20 and then incubated with the appropriate primary antibodies overnight at 4 °C. Membranes were washed with Tris-buffered saline with Tween-20 three times and then incubated with the appropriate horseradish peroxidase-conjugated secondary antibody for 1 h at 24 °C. Immunoreactive bands were detected with the BeyoECL Plus reagent (P0018, Beyotime) using a Photo-Image System (Molecular Dynamics, Sunnyvale, CA, United States). The primary antibodies used for blotting were as follows: Crif1 (M-222) (sc-134882; Santa Cruz), RANK (H-7) (sc-374360; Santa Cruz), A-FABP (AP2, sc-18661; Santa Cruz), PPARγ (sc-7273; Santa Cruz), β-actin (sc-47778; Santa Cruz), phospho-cAMP response element-binding protein (CREB) rabbit mAb (#9198; Cell Signaling Technology), and CREB rabbit mAb (#9197; Cell Signaling Technology).

**RT-qPCR**

RT-qPCR was used to analyze the mRNA levels of selected genes in collected samples. Total RNA was extracted using TRizol Reagent (catalog No. 10296010, Invitrogen) according to the manufacturer’s instructions. First-strand cDNA was synthesized from 1 µg of RNA using the PrimeScript RT Reagent Kit with gDNA Eraser (catalog No. RR047A, TaKaRa). qPCR was performed in triplicate in 20-µL reactions containing SYBR Premix Ex Taq II (catalog No. RR820A, TaKaRa). The reaction protocol was as follows: Heating for 30 s at 95 °C, followed by 40 cycles of amplification (5 s at 95 °C and 30 s at 60 °C).

The sequences of the RT-PCR primers are as follows: M-Crif1-F: GAAACGCTGGGAGAAAATTCA and M-Crif1-R: ATAGTTCCTGGAAGCGAGCA; M-actin-F: AGCCATGTACGTAGCCATCC and M-actin-R: CTCAGCTGTGGTGAGA; M-Rankl-F: GCTCCGAGCTGGTGAAGAAA and M-Rankl-R: CCCCAAAATGACATCGCAGTCCCTCTC; M-OPG-F: GTTCTGCACAGCTCTCCAA and M-OPG-R: AAACAGCACCAGT GCATCC.

**ELISA**

The concentrations of RANKL and OPG were measured using the Mouse RANKL ELISA Kit (E-EL-M0644c, elabscience), Human Soluble Receptor Activator of Nuclear Factor-kb Ligand ELISA Kit (E-EL-H5586c, elabscience), Mouse OPG ELISA Kit (E-EL-M0081c, elabscience), and Human OPG ELISA Kit (E-EL-H1341c, elabscience) according to the manufacturer’s instructions.

**Tartrate-resistant acid phosphatase staining**

After the 7-d coculture period, cells were washed once with PBS, fixed with 10% formalin for 10 min, and then incubated with a substrate solution, naphthol AS-BI phosphate (catalog No. 387, Sigma), in the presence of 50 mmol/L sodium tartrate at 37 °C for 1 h. The resulting mononuclear and multinuclear tartrate-resistant acid phosphatase (TRAP)-positive cells were visualized by light microscopy and quantified.

**Histomorphometric analysis**

Femurs were dissected, fixed overnight in 4% paraformaldehyde, decalcified in 10% EDTA (pH 7.0) for 20 d, and then embedded in paraffin. Longitudinally oriented sections of bone (4 µm thick), including the metaphysis and diaphysis, were processed for hematoxylin and eosin staining. Dewaxed sections were also stained for TRAP activity to identify osteoclasts. Sections were incubated in TRAP stain for 45 min at 37 °C.

**Crif1 inhibitor screening**

ClusPro and InterProSurf were used to investigate the interaction interface in Crif1-protein kinase cyclic adenosine monophosphate-activated catalytic subunit alpha (PRKACA) complex. Virtual screening using 462608 compounds from the Life Chemicals database around His120 of Crif1 was carried out using the program Autodock_vina. For inhibitor screening, H-BM-MSCs were cultured at a density of 1 × 10^5 cells per well in 6-well plates and pretreated with five different compounds (25 µmol/L). After 3 h of pretreatment, forskolin (25 µmol/L) was added to the medium. After 1 h of forskolin treatment, total protein lysates were extracted for CREB phosphorylation detection, and 3 d later, the supernatant medium was collected for ELISA.

**Tetrazolium salt (WST-8) assay**

A tetrazolium salt (WST-8) assay was carried out to study the toxicity of compounds to different cell lines, including human BM-MSCs, mouse BM-MSCs, and Vero cells. Cells seeded at a density of 3000 cells per well in 96-well plates were treated with five
different compounds at eight final concentrations (3.125 µmol/L, 6.25 µmol/L, 12.5 µmol/L, 25 µmol/L, 50 µmol/L, 100 µmol/L, 200 µmol/L, and 400 µmol/L). Three days later, 10 µL of cell counting kit-8 solution was added to each well. After 4 h of incubation, the absorbance at 450 nm was measured using a Varioskan FLASH microplate reader (Thermo).

**Statistical analysis**

The mRNA expression levels of RANKL and OPG in the tested samples were determined as the cycle threshold (CT) level, and normalized copy numbers (relative quantification) were calculated using the ΔΔCT equation as follows: \( \Delta\Delta CT = \Delta CT of the bone marrow sample - \Delta CT of \beta\text{-actin, and the normalized copy number (relative quantification) = } 2^{-\Delta\Delta CT}. \) The statistical significance of differences between the two groups was assessed using two-tailed Student’s t-tests. The statistical significance of differences among more than two groups was assessed using one-way ANOVA with Sidak’s multiple comparison tests. The statistical significance of differences between radiation treatments in mouse BM-MSCs and Crif1 knockout BM-MSCs experiments, radiation treatments in mouse BM-MSCs and Crif1 overexpressing BM-MSCs experiments, forskolin treatments in mouse BM-MSCs and Crif1-overexpressing BM-MSCs experiments were assessed using two-way ANOVA with Bonferroni’s or Sidak’s multiple comparison tests. All data are expressed as the mean ± standard deviation. A \( P \) value less than or equal to 0.05 was considered statistically significant.

**RESULTS**

**Radiation induces bone loss and increased Crif1 expression in mice**

To confirm the extent of bone loss over the short term after irradiation, we irradiated mice with a single dose of 5 Gy, and then, 7 d later, we harvested the left femurs. Micro-computed tomography analysis of the distal femurs of both males and females at 12 wk of age revealed significant decreases in trabecular bone volume/total volume (Figure 1A and B), connectivity density (Figure 1C), trabecular number (Figure 1D), and bone mineral density (Figure 1E), as well as significant increases in trabecular spacing (Figure 1G) and structure model index (Figure 1H). There was no significant difference in trabecular thickness (Figure 1F). Hematoxylin and eosin staining of femoral sections from irradiated mice showed significantly decreased trabecular bone (Figure 1I), while increased adipocytes (Figure 1J) compared to controls. Paraffin sections of femurs showed more TRAP-positive cells in irradiated mice than in control mice (Figure 1K), indicating the increased number of osteoclasts. These results indicated that radiation-induced adipogenesis and osteoclastogenesis. Moreover, RT-qPCR data revealed dramatic increases in RANKL expression (Figure 1L) and the RANKL/OPG ratio in irradiated bone marrow cells (Figure 1M). OPG expression was not affected by radiation treatment (Figure 1L). Notably, expression of Crif1 also increased in irradiated bone marrow cells compared with control cells 7 d after irradiation (Figure 1N and O).

**Overexpression of Crif1 in BM-MSCs increases RANKL secretion and osteoclastogenesis**

BM-MSCs are thought to be more resistant to radiation compared with other cells in the bone marrow, such as hematopoietic stem cells and T and B lymphocytes[23]. Moreover, BM-MSCs are the progenitors of bone marrow osteoblasts and adipocytes[24]. To investigate the role of Crif1 in osteoclastogenesis in vitro, we transfected mouse BM-MSCs with a Crif1 lentiviral overexpression vector (Figure 2A). For osteoclast induction in vitro, Crif1-overexpressing BM-MSCs and RAW264.7 cells were cocultured in a 12-well transwell unit for 7 d. RT-qPCR results showed that the relative mRNA expression of RANKL and RANKL/OPG ratio both increased in Crif1-overexpressing BM-MSCs compared to controls after 7 d of coculture (Figure 2B and C). Concentrations of RANKL and OPG in coculture medium were also detected by ELISA. Crif1-overexpressing BM-MSCs produced high levels of RANKL compared to the control (Figure 2D), while there was no significant difference in OPG concentration between the two groups (Figure 2E). The RANKL/OPG ratio in Crif1-overexpressing BM-MSCs was higher than that in the control (Figure 2F). We also detected an increased number of TRAP-positive cells in RAW264.7 cells cocultured with Crif1-overexpressing BM-MSCs (Figure 2G and H). These data suggested that Crif1 could promote RANKL expression and may be involved in osteoclast differentiation.
Figure 1  Radiation induces bone loss and increased CR6-interacting factor-1 expression in mice. A: Micro-computed tomography images of the distal metaphysis of the femur. Mice (n = 6/group) were exposed to Co-60 gamma rays, and received 5 Gy of whole-body sublethal irradiation at a rate of 0.69 Gy/min; B-H: Micro-computed tomography analysis of the trabecular bone volume/total volume (B), connectivity density (C), trabecular number (D), bone mineral density (E), trabecular thickness (F), trabecular spacing (G), and structure model index (H); I: Hematoxylin-eosin staining of femoral sections from irradiated mice and controls. Femoral sections from irradiated mice showed significantly decreased trabecular bone compared to controls; J: Hematoxylin-eosin staining of femoral sections from irradiated mice and controls. Femoral sections from irradiated mice showed that adipocytes increased significantly in irradiated mice; K: Tartrate-resistant acid phosphatase staining of femoral sections from irradiated mice and controls; L: Real-time quantitative polymerase chain reaction (RT-qPCR) analysis of receptor activator of nuclear factor κB ligand and osteoprotegerin mRNA expression in flushed whole bone marrow; M: Receptor activator of nuclear factor κB ligand/osteoprotegerin ratio based on RT-qPCR results; N: RT-qPCR analysis of CR6-interacting factor-1 mRNA expression in flushed whole bone marrow; O: Western blot analysis of CR6-interacting factor-1 expression in flushed whole bone marrow. *P < 0.05, **P < 0.01, and the bars represent the mean ± SD. OPG: Osteoprotegerin; RANKL: Receptor activator of nuclear factor κB ligand; Crif1: CR6-interacting factor-1; BM: Bone marrow; SMI: Structure model index; BV/TV: Bone volume/total volume; Conn.D: Connectivity density; Tb.N: Trabecular number; vBMD: Bone mineral density; Tb.Sp: Trabecular spacing; Tb.Th: Trabecular thickness.

**Crif1 is involved in the regulation of RANKL expression after radiation**

RANKL provides the critical signal to induce osteoclast differentiation by binding to its receptor RANK (on haematopoietic progenitors, such as monocytes-macrophages)\(^6\). To further confirm whether Crif1 plays an important role in osteoclastogenesis after radiation, we knocked out Crif1 in RAW264.7 cells and BM-MSCs (Figures 3A and 3D), respectively. The deletion of Crif1 in RAW264.7 cells did
Figure 2 Overexpression of CR6-interacting factor-1 in bone marrow mesenchymal stem/stromal cells increases receptor activator of nuclear factor κB ligand secretion and osteoclastogenesis. A: Western blot analysis of CR6-interacting factor-1 (Crif1) expression in mouse bone marrow mesenchymal stem/stromal cells (BM-MSCs). Mouse BM-MSCs were transfected with a Crif1 lentiviral overexpression vector; B: Real-time quantitative polymerase chain reaction analysis of receptor activator of nuclear factor κB ligand (RANKL) and osteoprotegerin (OPG) mRNA expression in BM-MSCs and Crif1-overexpressing BM-MSCs. BM-MSCs and Crif1-overexpressing BM-MSCs were cocultured with RAW264.7, respectively; C: RANKL/OPG ratio based on real-time quantitative polymerase chain reaction results; D: Enzyme linked immunosorbent assay analysis of RANKL protein levels in coculture supernatant medium; E: Enzyme linked immunosorbent assay analysis of OPG protein levels in coculture supernatant medium; F: RANKL/OPG ratio in coculture supernatant medium; G: Tartrate-resistant acid phosphatase staining of RAW264.7 cells after 7 d of coculture; H: Average number of tartrate-resistant acid phosphatase-positive cells/well (arrow) from RAW264.7 cells in coculture. aP < 0.05, bP < 0.01, and the bars represent the mean ± SD. OPG: Osteoprotegerin; RANKL: Receptor activator of nuclear factor κB ligand; Crif1: CR6-interacting factor-1; BM-MSCs: Bone marrow mesenchymal stem/stromal cells; BM-MSCs-OV: Crif1-overexpressing BM-MSCs.

not affect the RANK expression or osteoclast differentiation (Figure 3A-C). We previously demonstrated that Crif1 expression was upregulated after radiation, and in this study, we found that RANKL expression and the RANKL/OPG ratio were also elevated after radiation (Figure 3E-G and I). Meanwhile, more TRAP-positive cells were found in RAW264.7 cells cocultured with BM-MSCs after radiation (Figure 3J and K). However, knocking out Crif1 in BM-MSCs could significantly reduce RANKL expression and the RANKL/OPG ratio both before and after radiation (Figure 3E-G and I). OPG expression was not affected by Crif1 deletion or radiation treatment (Figure 3E and H). Moreover, the number of TRAP-positive cells also decreased in Crif1 knockout BM-MSCs compared to the control after 7 d of coculture with or without radiation treatment (Figure 3F and K). These results further demonstrated that Crif1 can regulate RANKL expression, especially after radiation.

**Crif1 mediates adipogenesis and RANKL secretion in adipocytes**

After radiation exposure, the hematopoietic red marrow gradually turns yellow, which is also known as bone marrow fatting. Moreover, excessive numbers of adipocytes are often found in the bone marrow of patients with osteoporosis, and these adipocytes can also secrete RANKL and accelerate osteoclastogenesis[27]. To determine whether Crif1 affects RANKL expression in adipocytes, BM-MSCs were exposed to a single dose of 9 Gy and then grown in mouse mesenchymal stem cell adipogenic differentiation medium. Consistent with our previous research[24], more BM-MSCs became strongly predisposed to adipogenesis after radiation treatment. After 21 d of induction, the intensity of oil red O staining was significantly higher in irradiated BM-MSCs, and more adipocytes were found in this group. Important regulators during late adipogenesis, such as PPAR-γ and AP2, both increased after radiation treatment (Figure 4A-C). Here, we also found an obvious increase in
CR6-interacting factor-1 is involved in the regulation of receptor activator of nuclear factor κB ligand expression after radiation. A: Western blot analysis of CR6-interacting factor-1 (Crif1) and receptor activator of nuclear factor κB expression in RAW264.7 cells. Crif1 was knocked out in RAW264.7 cells (RAW264.7-KO); B: Tartrate-resistant acid phosphatase (TRAP) staining of RAW264.7-KO and controls after 7 d of coculture with mouse bone marrow mesenchymal/stromal cells (BM-MSCs); C: Average number of TRAP-positive cells/well (arrow) from RAW264.7-KO and controls after 7 d of coculture with mouse BM-MSCs; D: Western blot analysis of Crif1 expression in BM-MSCs. Crif1 was knocked out in mouse BM-MSCs (BM-MSCs-KO), and BM-MSCs-KO and controls were irradiated with Co-60 at a single dose of 9 Gy; E: Real-time quantitative polymerase chain reaction analysis of receptor activator of nuclear factor κB ligand (RANKL) and osteoprotegerin (OPG) mRNA expression in BM-MSCs and BM-MSCs-KO. BM-MSCs and BM-MSCs-KO were cocultured with RAW264.7; F: RANKL/OPG ratio based on real-time quantitative polymerase chain reaction results; G: Enzyme linked immunosorbent assay analysis of RANKL protein levels in coculture supernatant medium; H: Enzyme linked immunosorbent assay analysis of OPG protein levels in coculture supernatant medium; I: RANKL/OPG ratio in coculture supernatant medium; J: TRAP staining of RAW264.7 after 7 d of coculture; K: Average number of TRAP-positive cells/well (arrow) from RAW264.7 in coculture.

RANKL expression and RANKL/OPG ratio in irradiated BM-MSCs after adipogenic induction (Figure 4D–F and H). However, knocking out Crif1 in BM-MSCs reduced adipogenesis (Figure 4A–C), RANKL expression, and RANKL/OPG ratio (Figure 4D and F) with or without radiation treatment. OPG expression was not affected by Crif1 deletion or radiation treatment (Figure 4D and G). These data suggested that Crif1 mediates adipogenesis and RANKL secretion in adipocytes.

Crif1 promotes RANKL secretion by modulating the cAMP/PKA signaling pathway

The regulation of bone remodeling involves many factors, such as parathyroid
Figure 4  CR6-interacting factor-1 mediates adipogenesis and receptor activator of nuclear factor κB ligand secretion in adipocytes. A: Oil red O staining analysis of mouse bone marrow mesenchymal stem/stromal cells (BM-MSCs) after 21 d of adipogenic differentiation. Crif1 was knocked out in mouse BM-MSCs (BM-MSCs-KO), and knockout cells and controls were irradiated with 9 Gy of Co-60, and then treated with mouse mesenchymal stem cell adipogenic differentiation medium (Ad) to induce adipogenesis; B: The dye from oil red O staining was extracted using isopropanol, and the optical density at 510 nm was measured using Benchmark Plus; C: Western blot analysis of adipogenesis-related markers and transcription factors PPARγ and AP2 in mouse BM-MSCs after 21 d of adipogenic differentiation; D: Real-time quantitative polymerase chain reaction analysis of receptor activator of nuclear factor κB ligand (RANKL) and osteoprotegerin (OPG) mRNA expression in BM-MSCs and BM-MSCs-KO; E: RANKL/OPG ratio based on real-time quantitative polymerase chain reaction results; F: Enzyme linked immunosorbent assay analysis of RANKL protein levels in supernatant Ad; G: Enzyme linked immunosorbent assay analysis of OPG protein levels in supernatant Ad; H: RANKL/OPG ratio in supernatant Ad. *P < 0.05 vs control (BM-MSCs), †P < 0.01 vs control (BM-MSCs); ‡P < 0.01 between 9 Gy-BM-MSCs and 9 Gy-BM-MSCs-KO, and the bars represent the mean ± SD. BM-MSCs: Bone marrow mesenchymal stem/stromal cells; BM-MSCs-KO: Crif1 knockout mouse BM-MSCs; OPG: Osteoprotegerin; RANKL: Receptor activator of nuclear factor κB ligand.

hormone (PTH), vitamin D3, bonemarrow-derived growth factors, and cytokines including RANKL. One of the primary mechanisms of bone remodeling is PTH-induced adenosine 3',5'-monophosphate (cAMP), which activates PKA and leads to phosphorylation and activation of CREB resulting in RANKL production[28]. To verify the mechanism underlying Crif1-mediated upregulation of RANKL expression, PKA agonist (forskolin) and inhibitor (H-89) were added to the co-culture system. RANKL expression and the RANKL/OPG ratio were both increased remarkably after treatment with 25 µmol/L forskolin, however, these effects were significantly weakened in Crif1 knockout BM-MSCs (Figure 5A-C and E). In addition, RANKL expression and the RANKL/OPG ratio were both decreased when Crif1-overexpressing BM-MSCs and controls were treated with 20 µmol/L H-89 (Figure 5F-I and J). OPG expression was not affected by forskolin or H-89 treatment (Figure 5A, D, F, and H). TRAP-positive cells were increased significantly by adding forskolin, the most TRAP-positive cells were found in the coculture with forskolin-treated BM-MSCs, but this effect was also reduced by Crif1 deletion (Figure 5K and L). H-89 could inhibit osteoclastogenesis effectively, and the fewest TRAP-positive cells were found in the coculture with H-89-treated Crif1-overexpressing BM-MSCs and controls (Figure 5N and O). After the addition of forskolin, CREB phosphorylation was significantly increased in the control BM-MSCs but was dramatically inhibited in Crif1 knockout BM-MSCs (Figure 5M). We also observed that CREB phosphorylation was suppressed in both Crif1-overexpressing BM-MSCs and controls following exposure to H-89 (Figure 5P). These results demonstrated that Crif1 promotes RANKL expression through the cAMP/PKA signaling pathway.

**Crif1 inhibitors effectively suppress RANKL secretion and adipogenesis**
Xiang LX et al. Cri1 promotes osteoclastogenesis after radiation

A

B

C

D

E

F

G

H

I

J

K

L

M
Figure 5  CR6-interacting factor-1 promotes receptor activator of nuclear factor κB ligand secretion by modulating the cAMP/PKA signaling pathway.

A: Real-time quantitative polymerase chain reaction (RT-qPCR) analysis of receptor activator of nuclear factor κB ligand (RANKL) and osteoprotegerin (OPG) mRNA expression in bone marrow mesenchymal stem/stromal cells (BM-MSCs) and Crif1 knockout BM-MSCs treated with 25 μmol/L forskolin in the coculture with RAW264.7. B: RANKL/OPG ratio based on RT-qPCR results; C: Enzyme linked immunosorbent assay (ELISA) analysis of RANKL levels in coculture supernatant medium treated with 25 μmol/L forskolin; D: ELISA analysis of OPG levels in coculture supernatant medium treated with 25 μmol/L forskolin; E: RANKL/OPG ratio in coculture supernatant medium treated with 25 μmol/L forskolin; F: RT-qPCR analysis of RANKL and OPG mRNA expression in BM-MSCs and BM-MSCs-OV treated with 20 μmol/L H-89 in the coculture with RAW264.7; G: RANKL/OPG ratio based on RT-qPCR results; H: ELISA analysis of RANKL levels in coculture supernatant medium treated with 20 μmol/L H-89; I: ELISA analysis of OPG levels in coculture supernatant medium treated with 20 μmol/L H-89; J: RANKL/OPG ratio in coculture supernatant medium treated with 20 μmol/L H-89; K: Tartrate-resistant acid phosphatase (TRAP) staining of RAW264.7 cells in coculture treated with 25 μmol/L forskolin; L: Average number of TRAP-positive cells/well (arrow) from RAW264.7 cells in coculture treated with 25 μmol/L forskolin; M: Western blot analysis of phospho-cyclic adenosine monophosphate response element-binding protein phosphorylation levels in BM-MSCs in coculture treated with 25 μmol/L forskolin; N: TRAP staining of RAW264.7 in coculture treated with 20 μmol/L H-89; O: Average number of TRAP-positive cells/well (arrow) from RAW264.7 in coculture treated with 20 μmol/L H-89; P: Western blot analysis of phospho-cyclic adenosine monophosphate response element-binding protein phosphorylation levels in BM-MSCs in coculture treated with 20 μmol/L H-89; α: Phospho-CREB (p-CREB) treated with 20 μmol/L H-89; b: Phospho-CREB (p-CREB) treated with 20 μmol/L H-89; c: Phospho-CREB (p-CREB) treated with 20 μmol/L H-89; d: Phospho-CREB (p-CREB) treated with 20 μmol/L H-89; e: Phospho-CREB (p-CREB) treated with 20 μmol/L H-89; f: Phospho-CREB (p-CREB) treated with 20 μmol/L H-89; g: Phospho-CREB (p-CREB) treated with 20 μmol/L H-89; h: Phospho-CREB (p-CREB) treated with 20 μmol/L H-89; i: Phospho-CREB (p-CREB) treated with 20 μmol/L H-89; j: Phospho-CREB (p-CREB) treated with 20 μmol/L H-89; k: Phospho-CREB (p-CREB) treated with 20 μmol/L H-89; l: Phospho-CREB (p-CREB) treated with 20 μmol/L H-89; m: Phospho-CREB (p-CREB) treated with 20 μmol/L H-89; n: Phospho-CREB (p-CREB) treated with 20 μmol/L H-89; o: Phospho-CREB (p-CREB) treated with 20 μmol/L H-89; p: Phospho-CREB (p-CREB) treated with 20 μmol/L H-89; q: Phospho-CREB (p-CREB) treated with 20 μmol/L H-89; r: Phospho-CREB (p-CREB) treated with 20 μmol/L H-89; s: Phospho-CREB (p-CREB) treated with 20 μmol/L H-89; t: Phospho-CREB (p-CREB) treated with 20 μmol/L H-89; u: Phospho-CREB (p-CREB) treated with 20 μmol/L H-89; v: Phospho-CREB (p-CREB) treated with 20 μmol/L H-89; w: Phospho-CREB (p-CREB) treated with 20 μmol/L H-89; x: Phospho-CREB (p-CREB) treated with 20 μmol/L H-89; y: Phospho-CREB (p-CREB) treated with 20 μmol/L H-89; z: Phospho-CREB (p-CREB) treated with 20 μmol/L H-89.

Because of the central role of RANKL in osteoclastogenesis, it is the basis for a new therapy to inhibit bone loss. We used ChiusPro and InterProSurf to investigate the interaction interface in Crif1-PRKACA complex, and the results showed that Thr219, Gly220, Thr221, Glu223, and Phe229 of PRKACA interact with Ile121, Met129, Ile131, and Arg132 in the long alpha-helical region of Crif1, forming the binding interface (Figure 6A). Virtual screening using 462608 compounds from the Life Chemicals database around His320 of Crif1 was carried out using the program Autodock_vina. A set of 13 compounds was selected for experimental screening based on binding energy < -12.0 kcal/mol (Supplementary Table 1). The binding pattern in the best-scored ligand–protein complexes potentially contained multiple interactions dominated by hydrophobic amino acids (Figure 6B-F). Initially, a tetrachlorination salt (WST-8) assay was carried out to study the potentially toxic effects of these compounds on different cell lines, including human BM-MSCs, Vero cells, and mouse BM-MSCs (Supplementary Figures 1-3). The compounds F0382-0033, F3408-0076, F1430-0134, F3408-0031, and F1430-0130 showed low toxicity to hBM-MSCs at a concentration of 25 μmol/L (Figures 6G-6K). To determine whether these compounds could affect RANKL expression, H-BM-MSCs were pretreated with these compounds followed by treatment with forskolin. ELISA analysis of supernatant medium revealed that RANKL expression was dramatically decreased by treatment with five Crif1 inhibitors (Figure 7A). OPG expression could be significantly increased by F1430-0134, but there were no significant differences between the other four compounds and the control (Figure 7B). Moreover, RANKL/OPG ratios were also decreased by these five compounds compared with the control (Figure 7C). Crif1 is involved in adipogenesis[24], and adipocytes are also the source of RANKL in the bone marrow[25]. In order to study the inhibitory effects of these five compounds on adipogenic differentiation of BM-MSCs, H-BM-MSCs were pretreated with five different compounds (25 μmol/L) followed by adipogenic induction. Oil red O staining indicated that adipogenic differentiation of H-BM-MSCs was remarkably suppressed by the addition of these five compounds (Figure 7D and E). To further understand the mechanism, CREB phosphorylation was detected. Western blot analysis showed that CREB phosphorylation activated by forskolin was significantly inhibited by pretreatment with the five compounds (Figure 7F). These results showed that Crif1 inhibitors could effectively suppress RANKL secretion and adipogenesis by inhibiting
CREB phosphorylation.

**DISCUSSION**

Radiation exposure (due to radiotherapy, accidental causes, or terrorism) causes irreparable damage to tissues and organs, and both the bone marrow and bone architecture are devastated following radiation exposure. Irradiation causes rapid depletion of bone marrow, total extracted bone marrow cells in the irradiated mice, including the hematopoietic cell niches, collapsed by 65% ± 11% after 2 d, remaining at those levels through 10 d.[32] In contrast, the number of CD90+ , CD29+, CD45-, and CD11b+ BM-MSCs increased relatively.[33] Irradiation also changes the bone marrow microenvironment, and adipocytes are significantly increased after radiation in the medullary cavity, which can negatively regulate the hematopoietic microenvironment, inhibit hematopoiesis, and accelerate osteoclastogenesis.[32,33] Irradiation suppresses bone formation and elevates bone resorption, disturbing the balance between them and leading to a dramatic decline in trabecular bone.[34] There is a near-immediate reduction in the number of osteoblasts, but an increased number and activity of osteoclasts post-radiation therapy.[35] In this study, we treated mice with a single dose of 5 Gy to generate a model of radiation-induced osteoporosis. RANKL expression and RANKL/OPG ratios actually increased in the surviving bone marrow cells after radiation, which was consistent with a previous study.[36] Meanwhile, expression of Crif1 and bone resorption also increased, indicating a relationship between RANKL and Crif1 in osteoporosis.

BM-MSCs, which are a major and important component of the bone marrow microenvironment, are the progenitors of both bone marrow osteoblasts and adipocytes. The balance between osteogenic and adipogenic differentiation of BM-MSCs plays a pivotal role in supporting hematopoiesis and maintaining bone homeostasis.[37,38] Crosstalk between macrophages and BM-MSCs within the bone marrow is also important for bone homeostasis. Different macrophage phenotypes exert different biological effects on the differentiation of BM-MSCs. Moreover, the modulatory effects of BM-MSCs on osteoclast progenitors, such as the monocyte-macrophage lineage, could be mediated by secretion of soluble factors.[36,37] Compared to other cells in bone marrow, BM-MSCs are more resistant to radiation, so the remaining BM-MSCs that escape radiation killing is crucial for the bone marrow microenvironment.[38] Following radiation exposure, BM-MSCs appear to preferentially differentiate into adipocytes instead of osteoblasts. This can ultimately hinder the proper bone formation and lead to disorders associated with bone loss (e.g., osteoporosis) or increased adipocyte content, ultimately leading to hematopoietic progenitor cell depletion.[37] Excessive numbers of adipocytes are often found in the bone marrow of patients with osteoporosis. It is indicated that the shift of the cell differentiation of BM-MSCs to adipocytes rather than osteoblasts partly contributes to osteoporosis.[39] A recent study revealed that bone marrow adipocytes can also secrete RANKL and accelerate osteoclastogenesis.[33] We previously reported that Crif1 can promote the adipogenesis of BM-MSCs after radiation. Here, we found that Crif1 could also promote RANKL secretion by BM-MSCs after radiation, and the deletion of Crif1 in BM-MSCs and Crif1 inhibitors can reduce both adipogenesis and RANKL expression.

RANKL functions as an osteoclast-activating factor, and its binding to RANK induces the activation of transcription factors such as c-fos, NFAT, and nuclear factor kappa B in preosteoclasts and initiates several downstream signaling pathways, especially the NF-kB pathway.[40] As RANKL is the only known ligand for RANK, and RANK and RANKL are crucial in bone metabolism, it is important to understand how the expression levels of RANKL are regulated under normal and disease conditions. RANKL expression can be upregulated by many agents, such as PTH and forskolin. Forskolin can stimulate RANKL expression through the cAMP/PKA signaling pathway.[41] It has been proved that cytokines and hormones which promote osteoclast formation act first on osteoblast lineage cells to promote the production of RANKL.[40] In this study, following forskolin exposure, RANKL expression increased significantly in BM-MSCs. However, the deletion of Crif1 from BM-MSCs impairs the promotion of RANKL expression by forskolin. Moreover, overexpression of Crif1 in BM-MSCs does not increase RANKL expression upon exposure to a PKA inhibitor. Here, we further demonstrated that Crif1 could also promote RANKL expression through the cAMP/PKA signaling pathway.

Drugs for the treatment of osteoporosis could be divided into anabolic and antiresorptive categories. Bisphosphonates (including alendronate and ibandronate, target osteoclast), estrogen, selective estrogen receptor modulators, and denosumab...
Figure 6  CR6-interacting factor-1-protein kinase cyclic adenosine monophosphate-activated catalytic subunit alpha interaction model and the inhibition potential of the lowest toxic effect of compounds. A: CR6-interacting factor-1 (Crif1)-protein kinase cyclic adenosine monophosphate-activated catalytic subunit alpha (PRKACA) interaction model showing Crif1 (colored in rose red) and PRKACA (colored in cyan). Interface amino acids are shown as sticks and colored in rose red (for Crif1) and cyan (for PRKACA) and indicated as a zoomed-in view in the inset figure; B-F: Chemical structure of each inhibitor molecule and their docked pose on Crif1 (colored in rose red, surface view). Docked molecule (stick) and the amino acids involved in the hydrophobic interactions (light purple) are shown. F0382-0033 (B), F3408-0076 (C), F1430-0134 (D), F3408-0031 (E), and F1430-0130 (F); G-K: A tetrazolium salt (WST-8) assay was carried out to study the toxic effect of compounds on the H-BM-MSCs. F0382-0033 (G), F3408-0076 (H), F1430-0134 (I), F3408-0031 (J), and F1430-0130 (K). The bars represent the mean ± standard deviation. H-BM-MSCs: Human bone marrow mesenchymal stem/stromal cells.
Figure 7  CR6-interacting factor-1 inhibitors effectively suppress receptor activator of nuclear factor κB ligand secretion and adipogenesis. A: Enzyme linked immunosorbent assay (ELISA) analysis of receptor activator of nuclear factor κB ligand protein levels in the supernatant medium. Human bone marrow mesenchymal stem/stromal cells (H-BM-MSCs) were pretreated with five different compounds (25 µmol/L) followed by treatment with forskolin (25 µmol/L), and supernatant medium was collected for ELISA after 3 d; B: ELISA analysis of osteoprotegerin protein levels in supernatant medium; C: Receptor activator of nuclear factor κB ligand/osteoprotegerin ratio in supernatant medium; D: Oil red O staining analysis of H-BM-MSCs after 21 d of adipogenic differentiation. H-BM-MSCs were pretreated with five different compounds (25 µmol/L) followed by adipogenic induction; E: The dye from oil red O staining was extracted using isopropanol, and the optical density at 510 nm was measured using Benchmark Plus; F: Western blot analysis of cyclic adenosine monophosphate response element-binding protein phosphorylation levels. H-BM-MSCs were pretreated with five different compounds (25 µmol/L) followed by treatment with forskolin (25 µmol/L) and total protein lysates were extracted for cyclic adenosine monophosphate response element-binding protein phosphorylation detection after 1 h. *P < 0.05, **P < 0.01, and the bars represent the mean ± SD. OPG: Osteoprotegerin; RANKL: Receptor activator of nuclear factor κB ligand; CREB: Cyclic adenosine monophosphate response element-binding protein; H-BM-MSCs: Human bone marrow mesenchymal stem/stromal cells.

(an antibody to RANKL) are antiresorptive drugs, whereas PTH and its analogs are...
anabolic agents\textsuperscript{[43-45]}. However, long-term trials showed that these drugs had no effects on the prevention of hip fractures. Moreover, the adverse effects of these anti-osteoporotic drugs should also be considered, such as hypocalcemia, arthralgia, nausea, and especially the development of breast cancer and risks of cardiovascular events and thromboembolism associated with treatment with estrogen and selective estrogen receptor modulators\textsuperscript{[46]}. Mesenchymal stem/stromal cells (MSCs) are one of the favorite sources of cell-based therapy. MSCs-based preclinical studies in animal models suggest a great clinical application potential of both BM-MSCs and adipose tissue-derived MSCs for osteoporosis treatment. However, the bone marrow homing efficiency, the long-term survival, and the uncertainty of MSCs’ fate after cell transplantation are the main concerns on the clinical application of MSCs for osteoporosis\textsuperscript{[47]}. Therefore, it is necessary to look for alternative treatments with high efficiency but a few side effects. Because of the importance of RANKL in osteoclast differentiation, RANKL-secreting cells, which play a central role in osteoclastogenesis, are the targets of most antiresorptive agents\textsuperscript{[48,49]}. BM-MSCs could be the target cells, and improving bone marrow microenvironment based on the remaining BM-MSCs in the bone marrow of patients and accelerating osteogenesis based on their fate decision to osteoblast or adipocyte could be a potential treatment for patients with radiation-induced bone injury. Our studies demonstrated that Crif1 could promote RANKL expression and adiogenic differentiation of BM-MSCs after radiation, and this may provide a potential molecular target for osteoporosis treatment. Osteogenesis and adipogenesis in the bone marrow are inversely correlated, so reduced adipogenesis results in an increase in the osteoblast pool\textsuperscript{[50,51]}. Future drug screening should target not only the regulation of the balance between bone formation and bone resorption but also the balance between osteogenic and adiogenic differentiation.

In conclusion, we have demonstrated that Crif1 plays a crucial role in osteoclastogenesis by inducing RANKL expression through the cAMP/PKA signaling pathway in mice. Moreover, through screening, we have identified five Crif1 inhibitors targeting Crif1-PRKACA interaction interface that could dramatically reduce RANKL secretion and adipogenesis. But the specificity of these five compounds and their effects on bone metabolism, such as increasing bone formation and decreasing bone resorption and adipogenesis, still need further \textit{in vitro} and \textit{in vivo} research, and to be validated in clinical trials. This study nevertheless enriches current knowledge of the pathogenesis of radiation-induced osteoporosis and provides insights into potential therapeutic strategies for radiation-induced bone injury.

**ARTICLE HIGHLIGHTS**

**Research background**
Radiation induces rapid bone loss and enhances bone resorption and adipogenesis, leading to an increased risk of bone fracture. Receptor activator of nuclear factor κB ligand (RANKL) provides the crucial signal to induce osteoclast differentiation and plays an important role in bone resorption. However, the mechanisms of radiation-induced osteoporosis are not fully understood.

**Research motivation**
Current treatment of osteoporosis is based mainly on inhibiting bone resorption or stimulating bone generation to increase bone mass, however, the side-effects of some drugs affect long-term administration and adherence. There is still a lack of effective preventive or therapeutic method for radiation-induced bone injury. Therefore, it is necessary to look for alternative treatments with high efficiency but few side effects.

**Research objectives**
In this study, we aimed to investigate the role of CR6-interacting factor-1 (Crif1) in osteoclastogenesis after radiation and its possible mechanism.

**Research methods**
C57BL/6 mice were exposed to Co-60 gamma rays and received 5 Gy of whole-body sublethal irradiation at a rate of 0.69 Gy/min. For \textit{in vitro} study, mouse bone marrow mesenchymal stem/stromal cells (BM-MSCs) were irradiated with Co-60 at a single dose of 9 Gy. For osteoclast induction, monocyte-macrophage RAW264.7 cells were cocultured with mouse BM-MSCs for 7 d. ClusPro and InterProSurf were used to investigate the interaction interface in Crif1 and protein kinase cyclic adenosine monophosphate (cAMP)-activated catalytic subunit alpha (PRKACA) complex. Virtual screening using 462608 compounds from the Life Chemicals database around His120 of Crif1 was carried out using the program Autodock_vina. A tetrazolium salt (WST-8) assay was carried out to study the toxicity of compounds to different cells, including human BM-MSCs, mouse BM-MSCs, and Vero cells.

**Research results**
Crif1 expression increased in bone marrow cells after radiation in mice. Overexpression of Crif1 in mouse BM-MSCs and radiation exposure could increase RANKL secretion and promote osteoclastogenesis in vitro. Deletion of Crif1 in BM-MSCs could reduce both adipogenesis and RANKL expression, resulting in the inhibition of osteoclastogenesis. The deletion of Crif1 in RAW264.7 cells did not affect the RANK expression or osteoclast differentiation. Following treatment with protein kinase A (PKA) agonist ( forskolin) and inhibitor (H-89) in mouse BM-MSCs, Crif1 induced RANKL secretion via the cAMP/PKA pathway. Moreover, we identified the Crif1-PRKACA interaction interface by in silico studies and shortlisted interface inhibitors through virtual screening on Crif1. Five compounds dramatically suppressed RANKL secretion and adipogenesis by inhibiting the cAMP/PKA pathway.

Research conclusions
Crif1 promotes RANKL expression via the cAMP/PKA pathway, which induces osteoclastogenesis by binding to RANK on monocytes-macrophages in the mouse model. These results suggest a role for Crif1 in modulating osteoclastogenesis and provide insights into potential therapeutic strategies targeting the balance between osteogenesis and adipogenesis for radiation-induced bone injury.

Research perspectives
Because of the contribution of adipocytes to osteoporosis, future drug screening should target not only the regulation of the balance between bone formation and bone resorption but also the balance between osteogenic and adipogenic differentiation. Here, through screening, we identified five Crif1 inhibitors targeting Crif1-PRKACA interaction interface that could dramatically reduce RANKL secretion and adipogenesis. Our study provides insights into potential therapeutic strategies for radiation-induced bone injury.

REFERENCES

1. Green DE, Rubin CT. Consequences of irradiation on bone and marrow phenotypes, and its relation to disruption of hematopoietic precursors. Bone 2014; 63: 87-94 [PMID: 24607941 DOI: 10.1016/j.bone.2014.02.018]
2. Jia D, Gaddy D, Suva LJ, Corry PM. Rapid loss of bone mass and strength in mice after abdominal irradiation. Radiat Res 2011; 176: 624-635 [PMID: 21859327 DOI: 10.1667/rr2505.1]
3. Baxter NN, Habelmann EB, Tepper JE, Durham SB, Virmig BA. Risk of pelvic fractures in older women following pelvic irradiation. JAMA 2005; 294: 2587-2593 [PMID: 16304702 DOI: 10.1001/jama.294.20.2587]
4. Rachner TD, Khosla S, Hofbauer LC. Osteoporosis: now and the future. Lancet 2011; 377: 1276-1287 [PMID: 21450337 DOI: 10.1016/S0140-6736(10)62349-5]
5. Khosla S, Hofbauer LC. Osteoporosis treatment: recent developments and ongoing challenges. Lancet Diabetes Endocrinol 2017; 5: 898-907 [PMID: 28688769 DOI: 10.1016/S2213-8587(17)30188-2]
6. Teitelbaum SL. Bone resorption by osteoclasts. Science 2000; 289: 1504-1508 [PMID: 10968780 DOI: 10.1126/science.289.5484.1504]
7. Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature 2003; 423: 337-342 [PMID: 12748652 DOI: 10.1038/nature01653]
8. Boyce BF, Xing L. Biology of RANK, RANKL, and osteoprotegerin. Arthritis Res Ther 2007; 9 Suppl 1: S1 [PMID: 17634140 DOI: 10.1186/ar2165]
9. Wada T, Nakashima T, Hiroshi N, Penninger JM. RANKL-RANK signaling in osteoclastogenesis and bone disease. Trends Mol Med 2006; 12: 17-25 [PMID: 16350770 DOI: 10.1016/j.molmed.2005.11.007]
10. Nakashima T, Hayashi M, Fukunaga T, Kusaka K, Oh-Hora M, Feng JQ, Bonewald LF, Kodama T, Wutz A, Wagner EF, Penninger JM, Takayanagi H. Evidence for osteocyte regulation of bone homeostasis through RANKL expression. Nat Med 2011; 17: 1231-1234 [PMID: 21909105 DOI: 10.1038/nm.2452]
11. Boyce BF, Xing L. Functions of RANKL/RANK/OPG in bone modeling and remodeling. Arch Biochem Biophys 2008; 473: 139-146 [PMID: 18395508 DOI: 10.1016/j.abb.2008.03.018]
12. Nuttall ME, Gimble JM. Controlling the balance between osteoblastogenesis and adipogenesis and the consequent therapeutic implications. Curr Opin Pharmacol 2004; 4: 290-294 [PMID: 15414422 DOI: 10.1016/j.coph.2004.03.002]
13. Islam MS, Stemig ME, Takahashi Y, Hui SK. Radiation response of mesenchymal stem cells derived from bone marrow and human pluripotent stem cells. J Radiat Res 2015; 56: 269-277 [PMID: 25425005 DOI: 10.1093/jrr/riv098]
14. Alwood JS, Shahnazi M, Chicanza B, Schreurs AS, Kumar A, Bartolini A, Shirazi-Fard Y, Globus RK. Ionizing Radiation Stimulates Expression of Pro-Osteoclastogenic Genes in Marrow and Skeletal Tissue. J Interferon Cytokine Res 2015; 35: 480-487 [PMID: 25734366 DOI: 10.1089/jir.2014.0152]
15. Chung HK, Yi YW, Jung NC, Kim D, Suh JM, Kim H, Park KC, Song JH, Kim DW, Hwang ES, Yoon SH, Bae YS, Kim JM, Bae I, Shong M, Cr6-interacting factor 1 interacts with miR345 family proteins and modulates the cell cycle. J Biol Chem 2003; 278: 28079-28088 [PMID: 12716909 DOI: 10.1074/jbc.M212835200]
16. Ran Q, Hao P, Xiao Y, Xiang L, Ye X, Deng X, Zhao J, Li Z. CRIF1 interacting with CDK2 regulates bone marrow microenvironment-induced G0/G1 arrest of leukemia cells. PLoS One 2014; 9: e85328 [PMID: 24520316 DOI: 10.1371/journal.pone.0085328]
17. Park KC, Song KH, Chung HK, Kim H, Kim DW, Song JH, Hwang ES, Jung HS, Park SH, Bae I, Lee IK, Choi HS, Shong M, Cr6-interacting factor 1 interacts with orphan nuclear receptor Nur77 and inhibits its transactivation. Mol Endocrinol 2005; 19: 12-24 [PMID: 15492948 DOI: 10.1210/me.2004-0107]
18. Kang HJ, Hong YB, Kim JH, Bae I. CR6-interacting factor 2 (NRFR2) protein stability by proteasome-mediated degradation. J Biol Chem 2010; 285: 21258-21268 [PMID: 20427290 DOI: 10.1074/jbc.M109.084590]
19. Chen L, Ran Q, Xiang Y, Xiang L, Chen L, Li F, Wu J, Wu C, Li Z. Co-Activation of PKC-δ by CRIF1 Modulates Oxidative Stress in Bone Marrow Multipotent Mesenchymal Stromal Cells after Irradiation by...
Phosphorylating NRF2 Ser40. Theranostics 2017; 7: 2634-2648 [PMID: 28819452 DOI: 10.7150/thno.17853]

Ran Q, Xiang Y, Stephen P, Wu C, Li T, Lin SX, Li Z. CRF1-CDK2 Interface Inhibitors: An Unprecedented Strategy for Modulation of Cell Radiosensitivity. J Am Chem Soc 2019; 141: 1420-1424 [PMID: 30653304 DOI: 10.1021/jacs.8b10207]

Ran Q, Jin F, Xiang Y, Xiang L, Wang Q, Li F, Chen L, Zhang Y, Wu C, Zhou L, Xiao Y, Chen L, Wu J, Zhong JF, Li SC, Li Z. CRF1 as a potential target to improve the radiosensitivity of osteosarcoma. Proc Natl Acad Sci USA 2019; 116: 20511-20516 [PMID: 31548420 DOI: 10.1073/pnas.1906578116]

Greber BJ, Biert P, Leibundgut M, Leitner A, Aebesold R, Boehringer D, Ban N. Radiosome. The complete structure of the 55k mammalian mitochondrial ribosome. Science 2015; 348: 303-308 [PMID: 25837512 DOI: 10.1126/science.aaa3872]

Jung SB, Choi MJ, Ryu D, Yi HS, Lee SE, Chang JY, Chung HK, Kim YK, Kang SG, Lee JH, Kim KS, Kim HJ, Kim CS, Lee CH, Williams RW, Kim H, Lee HK, Anwers J, Shong M. Reduced oxidative capacity in macrophages results in systemic insulin resistance. Nat Commun 2019; 8: 1551 [PMID: 29674655 DOI: 10.1038/s41467-018-03998-z]

Zhang X, Xiang L, Ran Q, Liu Y, Xiang Y, Xiao Y, Chen L, Li F, Zhong JF, Li Z. CRF1 Promotes Adipogenic Differentiation of Bone Marrow Mesenchymal Stem Cells After Irradiation by Modulating the PKA/CREB Signaling Pathway. Stem Cells 2015; 33: 1915-1926 [PMID: 25483789 DOI: 10.1002/stem.2019]

Chen MF, Lin CT, Chen WC, Yang CT, Chen CC, Liao SK, Liu JM, Lu CH, Lee KD. The sensitivity of human mesenchymal stem cells to ionizing radiation. Int J Radiat Oncol Biol Phys 2006; 66: 244-253 [PMID: 16839703 DOI: 10.1016/j.ijrobp.2006.03.062]

Jiang Y, Jahagirdar BN, Reinhard RL, Schwartz RE, Keene CD, Ortiz-Gonzalez XR, Reyes M, Lenvik T, Lund T, Blackstad M, Du J, Alldrich S, Lisberg A, Low WC, Largaespada DA, Verfaillie CM. Pluripotency of mesenchymal stem cells derived from adult marrow. Nature 2002; 418: 41-49 [PMID: 12077606 DOI: 10.1038/nature00870]

Fan Y, Hanai H, Le PT, Bi R, Maridas D, DeMambro V, Figueroa CA, Kir S, Zhou X, Mannstadt M, Baron R, Bronson RT, Horowitz MC, Wu JY, Bilezikjian JP, Dempster DW, Rosen CJ, Lambe K. Parathyroid Hormone Directs Bone Marrow Cell Fate. Metab Cell 2017; 25: 661-672 [PMID: 28162969 DOI: 10.1038/cm.2017.001]

Kondo H, Guo J, Bringhurst FR. Cyclic adenosine monophosphate/cyclic GMP regulated protein kinase A mediates parathyroid hormone/parathyroid hormone-related protein receptor regulation of osteoclastogenesis and expression of RANKL and osteoprotegerin mRNAs in mouse bone marrow stromal cells. J Bone Miner Res 2002; 17: 1667-1679 [PMID: 12211438 DOI: 10.1074/jbmr.2002.17.9.1667]

Green DE, Adler BJ, Chan ME, Rubin CT. Devastation of adult stem cell pools by irradiation precedes collapse of trabecular bone quality and quantity. J Bone Miner Res 2012; 27: 749-759 [PMID: 22190044 DOI: 10.1002/jbmr.283]

Cao X, Wu X, Frassica D, Yu B, Pang L, Xian L, Wan M, Lei W, Armour M, Tryggvason K, Wong J, Wen CY, Lu WW, Frassica FJ. Irradiation induces bone injury by damaging bone marrow microenvironment for stem cells. Proc Natl Acad Sci USA 2011; 108: 1609-1614 [PMID: 21220327 DOI: 10.1073/pnas.1015359108]

Naveiras O, Nardi V, Wenzel PL, Haaschka PV, Faley M, Daley QG. Bone-marrow adipocytes as negative regulators of the haematopoietic microenvironment. Nature 2009; 460: 259-263 [PMID: 19516257 DOI: 10.1038/nature08099]

D’Oronzo S, Stucci S, Tucci M, Silvestris F. Cancer treatment-induced bone loss (CTIBL): pathogenesis and clinical implications. Cancer Treat Rev 2015; 41: 798-808 [PMID: 26410578 DOI: 10.1016/j.ctrv.2015.09.003]

Pacheco R, Stock H. Effects of radiation on bone. Curr Osteoporos Rep 2013; 11: 299-304 [PMID: 24057133 DOI: 10.1007/s11914-013-0174-z]

Mori K, Suzuki K, Hozumi A, Goto H, Tomita M, Koseki H, Yamashita S, Osaki M. Potentiation of osteostostasis by adipogenic conversion of bone marrow-derived mesenchymal stem cells. Biomed Res 2014; 35: 153-159 [PMID: 24751983 DOI: 10.2220/biomedres.35.153]

Yue R, Zhou BO, Shimada IS, Zhao Z, Morrison SJ. Leptin Receptor Promotes Adipogenesis and Reduces Osteogenesis by Regulating Mesenchymal Stromal Cells in Adult Bone Marrow. Cell Stem Cell 2016; 18: 782-796 [PMID: 27055289 DOI: 10.1016/j.stem.2016.02.015]

He XT, Li X, Yin Y, Wu RX, Xu YY, Chen FM. The effects of conditioned media generated by polarized macrophages on the cellular behaviours of bone marrow mesenchymal stem cells. J Cell Mol Med 2018; 22: 1302-1315 [PMID: 29106032 DOI: 10.1111/jcmm.13431]

Sharaf-Eldin WE, Abu-Shahba N, Mahmoud M, El-Badri N. The Modulatory Effects of Mesenchymal Stem Cells on Osteostosisis. Stem Cells Int 2016; 2016: 1908365 [PMID: 26823668 DOI: 10.1155/2016/1908365]

Fekete N, Erle A, Amann EM, Fürst D, Rojewski MT, Langonné A, Sensebel L, Schrezenmeier H, Schmidtke-Schrezenmeier G. Effect of high-dose irradiation on human bone-marrow-derived mesenchymal stromal cells. Tissuc Eng Part C Methods 2015; 21: 112-122 [PMID: 24186644 DOI: 10.1089/ten.TEC.2013.0766]

Liao L, Yang X, Su X, Hu C, Zha X, Yang N, Chen X, Shi S, Shi S, Jin Y. Redundant miR-3077-5p and miR-705 mediate the shift of mesenchymal stem cell lineage commitment to adipocyte in osteoporosis bone marrow. Cell Death Dis 2013; 4: e600 [PMID: 23598412 DOI: 10.1038/cddis.2013.130]

Nakashima T, Hayashi M, Takayanagi H. New insights into osteostostic signaling mechanisms. Trends Endocrinol Metab 2012; 23: 582-590 [PMID: 22705116 DOI: 10.1016/j.tem.2012.05.005]

Tseng W, Graham IS, Geng Y, Reddy A, Lu J, Effros RB, Bemer L, Tintut Y. PKA-induced receptor activator of NF-kappab ligand (RANKL) expression in vascular cells mediates osteostosisis but not matrix calcification. J Biol Chem 2010; 285: 29925-29931 [PMID: 20663885 DOI: 10.1074/jbc.M110.117362]

Martin TJ, Sims NA. RANKL/OPG; Critical role in bone physiology. Rev Endocr Metab Disord 2015; 16: 119-131 [PMID: 25557611 DOI: 10.1007/s11154-014-9098-x]

Torstrick FB, Gulberg RE. Local strategies to prevent and treat osteoporosis. Curr Osteoporos Rep 2014; 12: 33-40 [PMID: 24510761 DOI: 10.1007/s11914-014-0191-6]

Andreopoulou P, Bockman RS. Management of postmenopausal osteoporosis. Annu Rev Med 2015; 66: 329-342 [PMID: 25366813 DOI: 10.1146/annurev-med-070313-122241]

Favus MJ. Bisphosphonates for osteoporosis. N Engl J Med 2010; 363: 2027-2035 [PMID: 2183837]
Xiang LX et al. Crf1 promotes osteoclastogenesis after radiation

DOI: 10.1056/NEJMct1004903

46 Khan M, Cheung AM, Khan AA. Drug-Related Adverse Events of Osteoporosis Therapy. Endocrinol Metab Clin North Am 2017; 46: 181-192 [PMID: 28131131 DOI: 10.1016/j.ecl.2016.09.009]

47 Hu L, Yin C, Zhao F, Ali A, Ma J, Qian A. Mesenchymal Stem Cells: Cell Fate Decision to Osteoblast or Adipocyte and Application in Osteoporosis Treatment. Int J Mol Sci 2018; 19 [PMID: 29370110 DOI: 10.3390/ijms19020360]

48 Tella SH, Gallagher JC. Prevention and treatment of postmenopausal osteoporosis. J Steroid Biochem Mol Biol 2014; 142: 155-170 [PMID: 24176761 DOI: 10.1016/j.jsbmb.2013.09.008]

49 Dempster DW, Lambing CL, Kostenuik PJ, Grauer A. Role of RANK ligand and denosumab, a targeted RANK ligand inhibitor, in bone health and osteoporosis: a review of preclinical and clinical data. Clin Ther 2012; 34: 521-536 [PMID: 22440513 DOI: 10.1016/j.clinthera.2012.02.002]

50 Muruganandan S, Roman AA, Sinal CJ. Adipocyte differentiation of bone marrow-derived mesenchymal stem cells: cross talk with the osteoblastogenic program. Cell Mol Life Sci 2009; 66: 236-253 [PMID: 18854943 DOI: 10.1007/s00018-008-8429-z]

51 Nuttall ME, Gimble JM. Is there a therapeutic opportunity to either prevent or treat osteopenic disorders by inhibiting marrow adipogenesis? Bone 2000; 27: 177-184 [PMID: 10913909 DOI: 10.1016/s8756-3282(00)00317-3]
